Published in Cell Death Dis on November 14, 2013
Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88
Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins. MAbs (2017) 0.75
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev (2017) 0.75
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood (2011) 2.47
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Is TRAIL the holy grail of cancer therapy? Apoptosis (2009) 1.62
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther (2012) 1.40
Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem (2000) 1.33
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res (2005) 1.29
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene (2001) 1.22
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res (2005) 1.17
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer (2004) 1.09
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis (2010) 1.06
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol (2007) 0.98
Engineering death receptor ligands for cancer therapy. Cancer Lett (2011) 0.89
CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. Eur J Immunol (1988) 0.85
Production, purification, and characterization of scFv TNF ligand fusion proteins. Methods Mol Biol (2012) 0.79
Gaussian models for genetic linkage analysis using complete high-resolution maps of identity by descent. Am J Hum Genet (1993) 8.05
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
Statistical methods for mapping quantitative trait loci from a dense set of markers. Genetics (1999) 5.05
NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol (2001) 3.02
Statistical methods for linkage analysis of complex traits from high-resolution maps of identity by descent. Genetics (1995) 2.64
Mapping quantitative trait loci in oligogenic models. Biostatistics (2001) 2.41
Combining information within and between pedigrees for mapping complex traits. Am J Hum Genet (1997) 2.33
The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A (1998) 2.26
The nucleolus. Curr Opin Cell Biol (1994) 1.90
Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.60
Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J (1999) 1.59
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 1.55
TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol (1999) 1.52
Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ (2006) 1.50
Preventing post-treatment bacteremia: comparing topical povidone-iodine and chlorhexidine. J Am Dent Assoc (1995) 1.50
Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J Immunol (1997) 1.43
Multipoint linkage analysis using affected relative pairs and partially informative markers. Biometrics (1998) 1.43
Identification of the cytolinker plectin as a major early in vivo substrate for caspase 8 during CD95- and tumor necrosis factor receptor-mediated apoptosis. Mol Cell Biol (2000) 1.40
Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother (2001) 1.28
Rapid molecular typing of methicillin-resistant Staphylococcus aureus by PCR-RFLP. Infect Control Hosp Epidemiol (2001) 1.28
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene (2000) 1.27
TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol (1998) 1.23
The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem (1999) 1.22
TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ (2009) 1.20
TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol (1998) 1.20
The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem (2000) 1.18
TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem (1998) 1.17
Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. FEBS Lett (2000) 1.16
p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene (2001) 1.16
Assigning functions to nucleolar structures. Chromosoma (1991) 1.14
Clonal heterogeneity, distribution, and pathogenicity of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1997) 1.13
THE LIMITING DISTRIBUTION OF THE LAST TIME s(n) >/= nin. Proc Natl Acad Sci U S A (1968) 1.12
Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ (2007) 1.11
Approximate p-values for local sequence alignments: numerical studies. J Comput Biol (2001) 1.11
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia (2008) 1.11
Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp--a molecular-epidemiological study. Wien Klin Wochenschr (2000) 1.10
Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene (2009) 1.04
Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology (2002) 1.04
Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer (1998) 1.02
Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet Cell Genet (1998) 1.01
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis (2010) 1.01
In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother (2001) 0.99
[The glutamic acid decarboxylase disc test. An approach for the simplification and speeding up of E. coli detection]. Zentralbl Bakteriol Mikrobiol Hyg B (1988) 0.98
Dynamic expression of Drosophila TRAF1 during embryogenesis and larval development. Mech Dev (2001) 0.97
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother (2001) 0.97
Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ (2010) 0.95
Rapid detection of epidemic strains of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (1999) 0.93
Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int J Antimicrob Agents (2000) 0.93
Mapping quantitative traits with random and with ascertained sibships. Proc Natl Acad Sci U S A (2004) 0.93
Serotyping, sites of isolation and resistance of Pseudomonas aeruginosa. Microbiologica (1988) 0.92
Structure of hydroxynitrile lyase from Manihot esculenta in complex with substrates acetone and chloroacetone: implications for the mechanism of cyanogenesis. Acta Crystallogr D Biol Crystallogr (2001) 0.92
New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur J Clin Microbiol Infect Dis (2000) 0.91
Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol (2010) 0.91
Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection (2005) 0.91
Continuous autotropic signaling by membrane-expressed tumor necrosis factor. J Biol Chem (1999) 0.90
Continuous intravenous vasopressin in active upper gastrointestinal bleeding. Ann Intern Med (1982) 0.89
QTL mapping under ascertainment. Ann Hum Genet (2006) 0.88
Protein kinase Cmu downregulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-kappaB-dependent protective genes. Eur J Biochem (1998) 0.88
Tumor necrosis factors in 1996. Cytokine Growth Factor Rev (1996) 0.87
Molecular cloning of acetone cyanohydrin lyase from flax (Linum usitatissimum). Definition of a novel class of hydroxynitrile lyases. J Biol Chem (1997) 0.87
Probability distributions related to the law of the iterated logarithm. Proc Natl Acad Sci U S A (1969) 0.87
TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis (2011) 0.87
Transduction of resistance to Imipenem, Aztreonam and Ceftazidime in nosocomial strains of Pseudomonas aeruginosa by wild-type phages. Acta Virol (1993) 0.86
Extended-spectrum beta-lactamase producing strains of Enterobacter cloacae transferring resistance to cefotaxime and ceftazidime. J Chemother (1999) 0.85
Crystallization and preliminary x-ray diffraction analysis of hydroxynitrile lyase from cassava (Manihot esculenta). Acta Crystallogr D Biol Crystallogr (1999) 0.85
Six enteropathogens isolated from a case of acute gastroenteritis. Infection (1991) 0.84
Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family. Curr Drug Targets (2009) 0.84
Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ (2006) 0.83
Sequential medical trials. Proc Natl Acad Sci U S A (1980) 0.83
Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) (2000) 0.83
Mechanistic aspects of cyanogenesis from active-site mutant Ser80Ala of hydroxynitrile lyase from Manihot esculenta in complex with acetone cyanohydrin. Protein Sci (2001) 0.83
Activation of the aryl hydrocarbon receptor sensitises human keratinocytes for CD95L- and TRAIL-induced apoptosis. Cell Death Dis (2012) 0.83
Evaluation of modern agglutination tests for identification of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1999) 0.83
Medical and veterinary use of antimicrobial agents: implications for public health. A clinician's view on antimicrobial resistance. Vet Microbiol (1993) 0.83
Imipenem and cefotaxime resistance: transduction by wild-type phages in hospital strains of Pseudomonas aeruginosa. J Chemother (1992) 0.83
Organization of the human tumour necrosis factor receptor-associated factor 1 (TRAF1) gene and mapping to chromosome 9q33-34. Gene (1997) 0.81
A 3D high-resolution gamma camera for radiopharmaceutical studies with small animals. Appl Radiat Isot (2003) 0.80
Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers. J Antimicrob Chemother (1988) 0.80
Looking at Christmas trees in the nucleolus. Chromosoma (1997) 0.80
Hydroxynitrile lyases in stereoselective catalysis. Curr Opin Biotechnol (2000) 0.79
Preliminary results of an interdisciplinary survey of drug victims. Forensic Sci Int (1993) 0.79
Further studies of transferable antibiotic resistance in strains of Pseudomonas aeruginosa from four clinical settings in three countries. J Chemother (1998) 0.78
Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. Microbiological and Clinical Study Groups. J Antimicrob Chemother (1992) 0.78
[Toxic shock syndrome in a 29-year-old patient]. MMW Munch Med Wochenschr (1981) 0.78
Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection (1991) 0.78
Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. J Interferon Cytokine Res (1996) 0.78
Bacteriophages transducing antibiotic resistance from a cluster of lysogenic strains of Pseudomonas aeruginosa isolated from patients. J Chemother (2001) 0.78
A model for penicillin production with and without temperature shift after the growth phase. Appl Microbiol Biotechnol (1992) 0.77
[Antibacterial effectiveness of povidone-iodine (Betaisodona) against highly resistance gram positive organisms]. Zentralbl Hyg Umweltmed (1998) 0.76
Concentration of ciprofloxacin in bone tissue after single parenteral administration to patients older than 70 years. Infection (1990) 0.76
[Bacteremia due to intraligamental anesthesia]. Zahnarztl Mitt (1986) 0.75